The opening of Eisai's new facility in Cambridge, Massachusetts, US.

JJapanese pharmaceutical company Eisai has opened a new facility in Massachusetts, US, to house its H3 Biomedicine unit.

The company has pledged that it will invest $200m into research funding at the centre, and intends to recruit a team of 70 to research innovative cancer treatments.

The facility will undertake the development of drugs designed to treat challenging cancers through advances in synthetic organic chemistry, with the overall aim of creating breakthrough drugs that are more precise and efficacious than existing therapies.

The unit will focus research into two main principles; identifying drug targets that define the root cause of the cancer and using synthetic organic chemistry to develop a library of compounds, used to develop novel small-molecule drugs against cancers previously thought of as ‘undruggable’.

H3 Biomedicine was originally established in December 2010 as a subsidiary of Eisai.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Caption: The opening of Eisai’s new facility in Cambridge, Massachusetts, US.